Objective: Ankylosing spondylitis (AS) is a chronic inflammatory disease of the spine and sacroiliac joints of unknown etiology.
Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory disease of the spine and sacroiliac joints of unknown etiology (1) . Increased oxidative stress is implicated in the pathogenesis of some diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Recent studies have also reported increased oxidative stress in AS (2) (3) (4) (5) .
Under normal conditions, there is a balance between oxidative damage and antioxidant defense. Insufficient antioxidant defense or increased production of reactive oxygen species (ROS) generates a condition known as oxidative stress (6) .
Oxidative stress can be measured by total antioxidant status (TAS) and total oxidant status (TOS), systematic reflections of it. Because the separate measurement of different oxidant and antioxidant molecules is not practical and their oxidant and antioxidant effects are cumulative, the total oxidant and antioxidant capacity of a sample is measured instead, providing TOS and TAS values, respectively (7) .
This may help to explain the pathogenesis. Insufficient data are available concerning the relations between oxidative stress, antioxidative capacity, and disease activity or biological treatment in AS.
Further studies on the subject are needed. The primary aim of this study was to investigate oxidative stress and related factors in AS. 
Material and Methods
Patients and controls Eighty-five patients with AS meeting the Modified New York criteria (6) and with no known acute or chronic diseases were included. The exclusion criteria were hypertension (HT), diabetes mellitus (DM), hyperlipidemia, and cigarette use. Fifty-six healthy controls subject to the same exclusion criteria as the patients were recruited from among the relatives of health professionals and blood donors. Patients receiving corticosteroid therapy within 8 weeks of the beginning of the study were also excluded. The disease duration and a detailed history of biological treatment were recorded.
Patients were also evaluated using the Bath ankylosing spondylitis metrology index (BASMI) (range: 0-10)(8), Bath ankylosing spondylitis functional index (BASFI) (range: 0-10) (9, 10), and Bath ankylosing spondylitis disease activity index (BASDAI) (range: 0-10) (11, 12) . Written informed consent was obtained from each subject, and research protocols were approved by the Local Ethical Committee.
Definition of variables
Hypertension: Average systolic BP ≥140 mmHg or average diastolic BP ≥90 mmHg or receiving treatment for HT (13).
Dyslipidemia: Total cholesterol level ≥260 mg/ dL or low density lipoprotein (LDL) cholesterol ≥160 mg/dL or the use of lipid lowering medication (14).
Diabetes mellitus (DM): Current use of medications prescribed to treat DM or fasting serum glucose levels ≥126 mg/dL (15) .
Smoking: Any tobacco consumption in the previous 30 days.
Active AS disease: Patients with BASDAI ≥4 at the time of the study were defined as having active disease.
Laboratory tests: Blood samples were collected for tests after overnight fasting. The erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), fasting blood glucose, and serum lipids [total cholesterol, high density lipoprotein (HDL) cholesterol, LDL cholesterol, and triglycerides] were measured using standard methods. Serum measurement of hs-CRP was performed using enzyme-linked immunosorbent assay (ELISA). The serum total oxidant status (TOS, µmol H 2 O 2 Eq/L) and total antioxidant status (TAS, µmolTroloxEq/L) were measured using the method described by Erel (16, 17) .
Statistical analysis
The results are given as medians with minimum and maximum values. The comparison of continuous variables between groups was performed using the Mann-Whitney U test. Differences between categorical variables were analyzed using Fisher's exact test. The Kruskal-Wallis test was used to compare multiple groups, and the Mann-Whitney test was used for pairwise comparisons. Relationships between variables were analyzed using Spearman's rank correlation coefficient. A linear regression model was used to determine the independent risk factors for TOS. Enter methods was used for linear regression analysis.
Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) (version 16.0 SPSS Inc.; Chicago, Illinois, USA) software. A two-tailed p value of <0.05 was considered statistically significant.
Results
The study group consisted of 85 patients with AS [age 36 (16- ) years] were receiving conventional treatments (non-steroidal anti-inflammatory drugs and/or sulfasalazine), and none had been previously treated with anti-TNF-α agents. Age, sex distribution, BMI, waist circumference, acute phase reactants, disease activity indices, and TAS and TOS concentrations were similar in patients receiving anti-TNF-α blocking agents and those on conventional drug s (p>0.05; Table 2 ). B-Comparison of subjects based on disease activity Forty-four patients with AS had active disease (BASDAI >4).The TOS concentrations were significantly higher in patients with active disease than in inactive patients and healthy controls (Table 3) . However, the TOS levels were not significantly different between the patients with inactive disease and the healthy controls. The TAS concentrations were similar between the groups.
C-Correlation and regression analysis
Correlation analysis yielded significant correlations between TOS and TAS, BASMI, BASFI, BAS-DAI, ESR, and hs-CRP (p<0.05; r=0.291, 0.451, 0.271, 0.363, 0.456, and 0.437, respectively). The highest correlation values were between TOS and BASDAI ( Figure 1 ). In addition, a positive correlation was observed between TAS and BASMI (p<0.05; r=0.344). At regression analysis, BASMI, BASDAI, and CRP independently predicted TOS levels (Table 4) . R² was found to be 0.262, and the standard error of the estimate (SEE) was found to be 10.96 for this model.
Discussion
In this study, patients with active AS patients had significantly higher TOS levels than the inactive group. The TAS levels were the same in all groups. The TOS and TAS concentrations were similar between patients treated with biologics and those receiving conventional agents.
The TOS levels were correlated with TAS, BAS-DAI, BASMI, and hs-CRP, but this correlation was low or moderate. The TOS levels are thought to be associated with activity and inflammation.
Markers of increased oxidative stress have previously been reported in AS (3) (4) (5) . Some studies have also reported that oxidative stress is more pronounced in the active disease status (3, 4) . In agreement with previous studies, we observed an increase in TOS in AS, and subgroup analysis revealed higher TOS levels in AS patients with active disease than in healthy controls. Additionally, BASDAI independently predicted the TOS levels. : 0.123 r: 0.457 tioxidants in vivo. We attributed our findings for TAS to uncompensated increased protective antioxidative total response to oxidative stress. Similar to our results, a significant increase in TOS and a significant decrease in TAS have also been observed in patients with coronary artery disease. This indicates an imbalance between oxidant and antioxidant molecules (18) . This situation may also contribute to cardiovascular risk in AS.
Pro-inflammatory cytokines (particularly TNF-α) have in recent years been shown to increase oxidative stress (19) . A number of studies have reported a decreased in the oxidation response with a TNF-α targeting agent (20, 21) . To the best of our knowledge, only one study has investigated the effect of anti-TNF-α on oxidative stress. In that study, Feijoo et al. (2) reported that infliximab therapy caused a decrease in oxidative stress biomarkers. In the current study, however, the TOS concentrations did not differ between patients treated with conventional or biological agents and healthy controls.
The exact mechanisms involved in the increased oxidative stress in AS are unknown, but the correlation of TOS with ESR and hs-CRP and increased TOS levels in active AS suggests that disease-related factors are involved.
One limitation of this study is its cross-sectional nature. The pre-treatment TOS/TAS levels were unavailable, making it difficult to discuss treatment efficacy.
In conclusion, oxidative stress increases in patients with AS, most probably mediated by inflammation. The TAS levels are insufficient to cope with the increased oxidative stress. The treatment status seems to have no effect on TOS. BASMI, BASDAI, and CRP emerge as independent related factors associated with TOS.
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